213 related articles for article (PubMed ID: 18204342)
1. A pilot study of adjunctive atomoxetine treatment to second-generation antipsychotics for cognitive impairment in schizophrenia.
Friedman JI; Carpenter D; Lu J; Fan J; Tang CY; White L; Parrella M; Bowler S; Elbaz Z; Flanagan L; Harvey PD
J Clin Psychopharmacol; 2008 Feb; 28(1):59-63. PubMed ID: 18204342
[TBL] [Abstract][Full Text] [Related]
2. Neural correlates of adjunctive rivastigmine treatment to antipsychotics in schizophrenia: a randomized, placebo-controlled, double-blind fMRI study.
Kumari V; Aasen I; ffytche D; Williams SC; Sharma T
Neuroimage; 2006 Jan; 29(2):545-56. PubMed ID: 16181792
[TBL] [Abstract][Full Text] [Related]
3. Implications for atypical antipsychotics in the treatment of schizophrenia: neurocognition effects and a neuroprotective hypothesis.
Jann MW
Pharmacotherapy; 2004 Dec; 24(12):1759-83. PubMed ID: 15585443
[TBL] [Abstract][Full Text] [Related]
4. A 12-week, double-blind, placebo-controlled trial of galantamine adjunctive treatment to conventional antipsychotics for the cognitive impairments in chronic schizophrenia.
Lee SW; Lee JG; Lee BJ; Kim YH
Int Clin Psychopharmacol; 2007 Mar; 22(2):63-8. PubMed ID: 17293705
[TBL] [Abstract][Full Text] [Related]
5. On the trail of a cognitive enhancer for the treatment of schizophrenia.
Stip E; Chouinard S; Boulay LJ
Prog Neuropsychopharmacol Biol Psychiatry; 2005 Feb; 29(2):219-32. PubMed ID: 15694228
[TBL] [Abstract][Full Text] [Related]
6. Augmenting atypical antipsychotics with a cognitive enhancer (donepezil) improves regional brain activity in schizophrenia patients: a pilot double-blind placebo controlled BOLD fMRI study.
Nahas Z; George MS; Horner MD; Markowitz JS; Li X; Lorberbaum JP; Owens SD; McGurk S; DeVane L; Risch SC
Neurocase; 2003 Jun; 9(3):274-82. PubMed ID: 12925933
[TBL] [Abstract][Full Text] [Related]
7. Effects of atomoxetine on cognitive function and cigarette smoking in schizophrenia.
Sacco KA; Creeden C; Reutenauer EL; Vessicchio JC; Weinberger AH; George TP
Schizophr Res; 2009 Feb; 107(2-3):332-3. PubMed ID: 18995989
[No Abstract] [Full Text] [Related]
8. A randomized double-blind trial of atomoxetine for cognitive impairments in 32 people with schizophrenia.
Kelly DL; Buchanan RW; Boggs DL; McMahon RP; Dickinson D; Nelson M; Gold JM; Ball MP; Feldman S; Liu F; Conley RR
J Clin Psychiatry; 2009 Apr; 70(4):518-25. PubMed ID: 19358788
[TBL] [Abstract][Full Text] [Related]
9. Atomoxetine augmentation of cholinesterase inhibitor therapy in patients with Alzheimer disease: 6-month, randomized, double-blind, placebo-controlled, parallel-trial study.
Mohs RC; Shiovitz TM; Tariot PN; Porsteinsson AP; Baker KD; Feldman PD
Am J Geriatr Psychiatry; 2009 Sep; 17(9):752-9. PubMed ID: 19700948
[TBL] [Abstract][Full Text] [Related]
10. Treatment of cognitive dysfunction in schizophrenia.
Peuskens J; Demily C; Thibaut F
Clin Ther; 2005; 27 Suppl A():S25-37. PubMed ID: 16198199
[TBL] [Abstract][Full Text] [Related]
11. Treatment of cognitive deficits in schizophrenia.
Bowie CR; Harvey PD
Curr Opin Investig Drugs; 2006 Jul; 7(7):608-13. PubMed ID: 16869112
[TBL] [Abstract][Full Text] [Related]
12. Procholinergic and memory enhancing properties of the selective norepinephrine uptake inhibitor atomoxetine.
Tzavara ET; Bymaster FP; Overshiner CD; Davis RJ; Perry KW; Wolff M; McKinzie DL; Witkin JM; Nomikos GG
Mol Psychiatry; 2006 Feb; 11(2):187-95. PubMed ID: 16231039
[TBL] [Abstract][Full Text] [Related]
13. Cognitive and psychomotor effects of risperidone in schizophrenia and schizoaffective disorder.
Houthoofd SA; Morrens M; Sabbe BG
Clin Ther; 2008 Sep; 30(9):1565-89. PubMed ID: 18840365
[TBL] [Abstract][Full Text] [Related]
14. Impact of modafinil on prefrontal executive function in schizophrenia.
Hunter MD; Ganesan V; Wilkinson ID; Spence SA
Am J Psychiatry; 2006 Dec; 163(12):2184-6. PubMed ID: 17151173
[TBL] [Abstract][Full Text] [Related]
15. [Interest of a new instrument to assess cognition in schizophrenia: The Brief Assessment of Cognition in Schizophrenia (BACS)].
Bralet MC; Navarre M; Eskenazi AM; Lucas-Ross M; Falissard B
Encephale; 2008 Dec; 34(6):557-62. PubMed ID: 19081451
[TBL] [Abstract][Full Text] [Related]
16. Effect of the selective norepinephrine reuptake inhibitor reboxetine on cognitive dysfunction in schizophrenia patients: an add-on, double-blind placebo-controlled study.
Poyurovsky M; Faragian S; Fuchs C; Pashinian A
Isr J Psychiatry Relat Sci; 2009; 46(3):213-20. PubMed ID: 20039523
[TBL] [Abstract][Full Text] [Related]
17. Treatment of cognitive dysfunction in chronic schizophrenia by augmentation of atypical antipsychotics with buspirone, a partial 5-HT(1A) receptor agonist.
Piskulić D; Olver JS; Maruff P; Norman TR
Hum Psychopharmacol; 2009 Aug; 24(6):437-46. PubMed ID: 19637398
[TBL] [Abstract][Full Text] [Related]
18. Atomoxetine increases histamine release and improves learning deficits in an animal model of attention-deficit hyperactivity disorder: the spontaneously hypertensive rat.
Liu LL; Yang J; Lei GF; Wang GJ; Wang YW; Sun RP
Basic Clin Pharmacol Toxicol; 2008 Jun; 102(6):527-32. PubMed ID: 18346050
[TBL] [Abstract][Full Text] [Related]
19. Neurocognitive effects of ziprasidone and related factors in patients with chronic schizophrenia undergoing usual care: a 12-month, open-label, flexible-dose, naturalistic observational trial.
Gibel A; Ritsner MS
Clin Neuropharmacol; 2008; 31(4):204-20. PubMed ID: 18670244
[TBL] [Abstract][Full Text] [Related]
20. Effect of the attention deficit/hyperactivity disorder drug atomoxetine on extracellular concentrations of norepinephrine and dopamine in several brain regions of the rat.
Swanson CJ; Perry KW; Koch-Krueger S; Katner J; Svensson KA; Bymaster FP
Neuropharmacology; 2006 May; 50(6):755-60. PubMed ID: 16427661
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
